XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue - Zai Lab (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 27 Months Ended
Jun. 30, 2021
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2019
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Jun. 15, 2021
Collaboration And Other Agreements [Line Items]                    
Revenues   $ 13,136 $ 26,007 $ 37,632 $ 37,108          
Common stock, par value (in dollars per share)   $ 0.01   $ 0.01       $ 0.01    
Deferred revenue, current   $ 9,671   $ 9,671       $ 9,988    
Deferred revenue, net of current portion   58,538   58,538       $ 59,480    
2018 Zai Lab Agreement | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment           $ 25,000        
Non-refundable upfront payment, net of tax withholding           22,500        
Nonrefundable payment tax withholding           $ 2,500        
Potential development and regulatory milestone payments under agreement                 $ 140,000  
Development and regulatory milestones recognized             $ 9,000      
Revenues   0 400 0 5,400          
Milestones Value Added Tax             $ 8,100      
Zai Lab Agreement, Margetuximab | Zai Labs | Maximum                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)           20.00%        
Zai Lab Agreement, TRIDENT molecule | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Potential proceeds from royalties (percent)           10.00%        
2021 Zai Lab Agreements | Zai Labs                    
Collaboration And Other Agreements [Line Items]                    
Non-refundable upfront payment $ 25,000                  
Potential development and regulatory milestone payments under agreement                   $ 680,000
Revenues   $ 0 $ 14,700 $ 0 $ 15,000          
Proceeds of stock sale 30,000                  
Sales of stock purchase price (in dollars per share)                   $ 31.3
Potential commercial milestone payments under agreement                   $ 600,000
Collaborative agreement transaction price                   $ 40,400
Variable consideration recognized 5,000                  
2021 Zai Lab Agreements | Zai Labs | Additional Paid-In Capital                    
Collaboration And Other Agreements [Line Items]                    
Premium received on stock purchase $ 10,400